NDLI: In vivo tumor targeting imaging of cyclic RGD-modified heparin derivative to α$_{v}$β$

Please wait, while we are loading the content...

Determination of three preservatives, cresol, chlorocresol and benzethonium, in drugs by high performance liquid chromatography–ultraviolet (HPLC–UV) detection

Effects of formulation on pharmacokinetics of docetaxel in rats

In vivo tumor targeting imaging of cyclic RGD-modified heparin derivative to α$_{v}$β$_{3}$-integrin expressing tumor

Content Provider	Springer Nature Link
Author	Byun, Youngro Park, Kyeongsoon Kim, Sung Eun Chin, Jungwook Lee, Hanna
Copyright Year	2012
Abstract	Therapeutic target for over-expressed α$_{v}$β$_{3}$ integrins in angiogenic endothelial cells and tumors is one of the promising approaches for cancer imaging and therapy. In the previous study, we demonstrated that heparin–lithocholic acid functionalized with cyclic RGDyK (cRGD–HL) had potent angiogenesis inhibition and tumor regression effects. The aim of this study is to validate the targeting property and specificity of cRGD–HL to α$_{v}$β$_{3}$ integrin-expressing endothelial cells and tumor tissues by Cy5.5-labeled cRGDyK (RGD-Cy5.5) as α$_{v}$β$_{3}$ integrin imaging agent and near-infrared fluorescence (NIRF) imaging systems. In this study, we demonstrated that cRGD–HL markedly inhibited the binding of fluorescein-labeled α$_{v}$β$_{3}$ antibody to α$_{v}$β$_{3}$ integrin-expressing endothelial cells when compared to non-functionalized heparin derivatives. Furthermore, in vivo NIRF images showed that cRGD–HL could decrease the NIRF signal intensities in both α$_{v}$β$_{3}$ integrin-positive tumor (U87 MG) and α$_{v}$β$_{3}$ integrin-negative tumor (SCC7) more effectively than non-functionalized heparin derivatives could. Therefore, with the help of α$_{v}$β$_{3}$ integrin imaging agent and NIRF imaging systems, we verified that the functionalized cRGD–HL has much stronger tumor targeting property and specificity against α$_{v}$β$_{3}$ integrin-expressing endothelial cells and tumors than non-functionalized heparin derivatives. Also, we believe that cRGD–HL will be useful and give affirmative outcomes for the treatment of angiogenesis-related diseases.
Starting Page	9
Ending Page	14
Page Count	6
File Format	PDF
ISSN	20935552
Journal	Journal of Pharmaceutical Investigation
Volume Number	42
Issue Number	1
e-ISSN	20936214
Language	English
Publisher	Springer Netherlands
Publisher Date	2012-02-02
Publisher Place	Dordrecht
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	α$_{v}$β$_{3}$ Integrin Heparin derivative Tumor targeting Optical imaging Cyclic RGD Biomedicine general
Content Type	Text
Resource Type	Article
Subject	Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of α$_{v}$β$_{3}$ integrin-overexpressing breast cancer cells

RGD-Based Molecular Probes for Integrin α v β 3 Imaging

Tumor Endothelial Cell Targeted Cyclic RGD-modified Heparin Derivative: Inhibition of Angiogenesis and Tumor Growth

Interaction between integrin α$_{IIb}$β$_{3}$ and synthesized cyclic hexapeptide containing RGD

Imaging of integrin αvβ3 expression

Kaempferol inhibits the production of ROS to modulate OPN–α$_{v}$β$_{3}$ integrin pathway in HUVECs

Dual effects of β$_{3}$ integrin subunit expression on human pancreatic cancer models

Binding and Uptake of RGD-Containing Ligands to Cellular α $_{v}$ β $_{3}$ Integrins

Fatty Acid–RGD Peptide Amphiphile Micelles as Potential Paclitaxel Delivery Carriers to α$_{v}$β$_{3}$Integrin Overexpressing Tumors

In vivo tumor targeting imaging of cyclic RGD-modified heparin derivative to α$_{v}$β$_{3}$-integrin expressing tumor

Similar Documents

RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of α$_{v}$β$_{3}$ integrin-overexpressing breast cancer cells

RGD-Based Molecular Probes for Integrin α v β 3 Imaging

Tumor Endothelial Cell Targeted Cyclic RGD-modified Heparin Derivative: Inhibition of Angiogenesis and Tumor Growth

Interaction between integrin α$_{IIb}$β$_{3}$ and synthesized cyclic hexapeptide containing RGD

Imaging of integrin αvβ3 expression

Kaempferol inhibits the production of ROS to modulate OPN–α$_{v}$β$_{3}$ integrin pathway in HUVECs

Dual effects of β$_{3}$ integrin subunit expression on human pancreatic cancer models

Binding and Uptake of RGD-Containing Ligands to Cellular α $_{v}$ β $_{3}$ Integrins

Fatty Acid–RGD Peptide Amphiphile Micelles as Potential Paclitaxel Delivery Carriers to α$_{v}$β$_{3}$Integrin Overexpressing Tumors

In vivo tumor targeting imaging of cyclic RGD-modified heparin derivative to α$_{v}$β$_{3}$-integrin expressing tumor